Head & Neck Cancers

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Lori Wirth, MD, discusses the safety selpercatinib in adult or pediatric patients with advanced or metastatic RET fusion–positive thyroid cancer.

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

The ROR2-targeted ADC ozuriftamab vedotin has received FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

Coral Olazagasti, MD, discusses disparities in lung cancer screening rates between Hispanic and non-Hispanic White survivors of head and neck cancer.

Lova Sun, MD, MSCE, discussions safety implications observed from part C of the phase 2 innovaTV 207 trial.

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

Ranee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.

Frontline eftilagimod alpha plus pembrolizumab was safe and elicited responses in patients with PD-L1–negative head and neck squamous cell carcinoma.

Lori Wirth, MD, discusses questions about the treatment of patients with RET fusion+ thyroid cancer following the full approval of selpercatinib.

Lori Wirth, MD, discusses the LIBRETTO-001 trial of selpercatinib for patients with advanced or metastatic RET fusion–positive thyroid cancer.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

The American Society for Radiation Oncology has released a guideline to characterize the place of radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Lori Wirth, MD, discusses the significance of the full FDA approval of selpercatinib for patients with advanced or metastatic RET fusion+ thyroid cancer.

The bifunctional antibody ficerafusp alfa plus pembrolizumab generated clinically meaningful activity in HPV–recurrent/metastatic HNSCC.

Coral Olazagasti, MD discusses a tailored lung cancer screening program for Hispanic head and neck cancer survivors.

Lova L. Sun, MD, MSCE discusses tisotumab vedotin (in patients with recurrent or metastatic (r/m) head and neck squamous cell carcinoma.

Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

Malcolm Mattes, MD, discusses the CTEP 10492 trial of ipatasertib plus chemoradiotherapy in locally advanced head and neck squamous cell carcinoma.

The FDA granted full approval to selpercatinib for select patients with advanced or metastatic RET fusion–positive thyroid cancer.

Versamune HPV in combination with pembrolizumab produced a durable median overall survival in patients with recurrent or metastatic HPV16-positive HNSCC.

Petosemtamab paired with pembrolizumab had early clinical efficacy when used as first-line treatment in select head and neck squamous cell carcinoma